NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Call Transcript

Suffice it to say that if you can get insurance coverage for people, payers have indicated a real willingness to pay for the therapy because the alternative of psychiatric hospitalization and electroshock therapy is something that — first of all, is horrible for patients. And second of all, costs payers the better part of $40,000 in the first year. So we believe there is a market opportunity but we’re certainly going to be guided by the security analysts as well.

Ed Woo: Great for the details. And thank you for answering my questions. I wish you guys good luck. Thank you.

Operator: There are no further questions at this time. I would like to turn the floor back to Matt Duffy for any closing remarks.

Matthew Duffy: Thank you, everyone. That’s all the time we have for today. We appreciate you joining us this morning and this concludes the NRx Pharmaceuticals fourth quarter ’23 and full year conference call. Thank you all for participating.

Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.